Prevalence of antiretroviral drug resistance mutations and HIV-1 subtypes among newly-diagnosed drug-naïve persons visiting a voluntary testing and counselling centre in northeastern South Africa

Journal of Health, Population and Nutrition

Volumn 29, Issue 4, 2011, Pages 303-309

  Nwobegahay, Julius M ^a   Bessong, Pascal O ^a   Masebe, Tracy M ^a   Mavhandu, Lufuno G ^a   Iweriebor, Benson C ^a   Selabe, Gloria ^b  

^a UNIVERSITY OF VENDA   (South Africa)

^b UNIVERSITY OF LIMPOPO   (South Africa)

Author keywords

Antiretrovirals; Drug resistance; Drug na ve persons; HIV 1; South Africa

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80053266394     PISSN: 16060997     EISSN: None     Source Type: Journal    
DOI: 10.3329/jhpn.v29i4.8444     Document Type: Article

References (24)

1. Tang JW, Pillay D. Transmission of HIV-1 drug resistance (review). J Clin Virol 2004;30:1-10.
2. Gatanaga H, Ibe S, Matsuda M, Yoshida S, Asagi T, Kondo M et al. Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. Antivir Res 2007;75:75-8.
3. Turner D, Wainberg MA. HIV transmission and primary drug resistance. AIDS Rev 2006;8:17-23.
4. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro J et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007;21:215-23.
5. Gupta RK, Pillay D. HIV resistance and the developing world. Int J Antimicrob Agents 2007;29:510-7.
6. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science 2009;323:1304-7.
7. South Africa. Department of Health. National HIV and syphilis seroprevalence survey-South Africa. Pretoria: Department of Health, Republic of South Africa, 2007:1-47.
8. South Africa. Department of Health. National antiretroviral treatment guidelines, South Africa. Pretoria: Department of Health, Republic of South Africa, 2010:1-8.
9. Pillay V, Ledwaba J, Hunt G, Rakgotho M, Singh B, Makubalo L et al. Antiretroviral drug resistance surveillance among drug-naïve HIV-1-infected individuals in Gauteng province, South Africa in 2002 and 2004. Antivir Therap 2008;2:101-7.
10. Bessong PO, Mphahlele J, Choge IA, Obi LC, Morris L, Hammarsskjold ML et al. Resistance mutational analysis of HIV type 1 subtype C among rural South African drug-naïve patients prior to large-scale availability of antiretrovirals. AIDS Res Hum Retroviruses 2006;22:1306-12.
11. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. HIV-1 clade C resistance genotypes in treatment-naïve patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Therap 2009;14:523-31.
12. Bessong PO, Obi CL, Cilliers T, Choge I, Phoswa M, Pillay C. Characterization of human immunodeficiency virus type 1 from a previously unexplored region of South Africa with a high HIV prevalence. AIDS Res Hum Retroviruses 2005;21:103-9.
13. GenBank overview. (http://www.ncbi.nlm.nih.gov/genbank, accessed on 29 June 2009).
14. Alcantara LC, Cassol S, Libin P, Deforche K, Pybus OG, Van Ranst M et al. A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. Nucleic Acids Res 2005;10:1-9.
15. De Oliveira T, Deforche K, Cassol S, Salminem M, Paraskevis D, Seebregts C et al.. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinfomatics 2005;21:3797-800.
16. BioEdit. (http://www.mbio.ncsu.edu/BioEdit/bioedit.html, accessed on 29 June 2009).
17. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antvir Therap 2008;2:25-36.
18. Taiwo B. Understanding transmitted HIV resistance through the experience in the USA. Int J Infect Dis 2009;13:552-9.
19. Jacobs GB, Laten A, van Rensburg EJ, Bodem J, Weissbrich B, Rethwilm A et al. Phylogenetic diversity of low level antiretroviral resistance mutations in HIV type 1 treatment-naïve patients from Cape Town, South Africa. AIDS Res Hum Retroviruses 2008; 24:1009-12.
20. Handema R, Terunuma H, Kasolo F, Kasai H, Sichone M, Yamashita A et al. Prevalence of drug-resistanceassociated mutations in antiretroviral drug-naïve Zambians infected with subtype C HIV-1. AIDS Res Hum Retroviruses 2003;19:151-60.
21. Kamoto K, Aberle-Grasse J. Malawi HIV Drug Resistance Task Force. Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir Therap 2008; 2:83-7.
22. Cane P, Chrystie I, Dunn D, Evans B, Geretti A, Green H et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2005;331:1368.
23. Smith D, Moini N, Pesano R, Cachay E, Aiem H, Lie Y et al. Clinical utility of HIV of standard genotyping among antiretroviral-naive individuals with unknown duration of infection. Clin Infect Dis 2007; 44;456-8.
24. Fisch1 M, Richman D, Grieco M, Gottlieb M, Volberding P, Laskin O. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:185-91.